Keefe T. Chan

Keefe T. Chan

Auto-generated profile, based on publicly available information

Keefe T. Chan

Peter MacCallum Cancer Centre, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2009 in Journal of Cell Biology
Verified
Journal Article
Open access
KCKeefe T. Chan
Keefe T. Chan
CCChrista L. Cortesio
Christa L. Cortesio
AHAnna Huttenlocher
Anna Huttenlocher
Focal adhesion kinase (FAK) is important for breast cancer progression and invasion and is necessary for the dynamic turnover of focal adhesions. However, it has not been determined whether FAK also regulates the dynamics of invasive adhesions formed in cancer cells known as invadopodia. In this study, we report that endogenous FAK functions upstream of cellular Src (c-Src) as a negative regulator of invadopodia formation and dynamics in breast cancer cells. We show that depletion of FAK induces the formation of active invadopodia but impairs invasive cell migration. FAK-deficient MTLn3 breast cancer cells display enhanced assembly and dynamics of invadopodia that are rescued by expression of wild-type FAK but not by FAK that cannot be phosphorylated at tyrosine 397. Moreover, our findings demonstrate that FAK depletion switches phosphotyrosine-containing proteins from focal adhesions to invadopodia through the temporal and spatial regulation of c-Src activity. Collectively, our findings provide novel insight into the interplay between FAK and Src to promote invasion.

10 March 2008 in Journal of Cell Biology
Verified
Journal Article
Open access
CCChrista L. Cortesio
Christa L. Cortesio
KCKeefe T. Chan
Keefe T. Chan
BPBenjamin J. Perrin
Benjamin J. Perrin
NBNick Burton
Nick Burton
SZSheng Zhang
Sheng Zhang
AHAnna Huttenlocher
Anna Huttenlocher
Invasive cancer cells form dynamic adhesive structures associated with matrix degradation called invadopodia. Calpain 2 is a calcium-dependent intracellular protease that regulates adhesion turnover and disassembly through the targeting of specific substrates such as talin. Here, we describe a novel function for calpain 2 in the formation of invadopodia and in the invasive abilities of breast cancer cells through the modulation of endogenous c-Src activity. Calpain-deficient breast cancer cells show impaired invadopodia formation that is rescued by expression of a truncated fragment of protein tyrosine phosphatase 1B (PTP1B) corresponding to the calpain proteolytic fragment, which indicates that calpain modulates invadopodia through PTP1B. Moreover, PTP1B activity is required for efficient invadopodia formation and breast cancer invasion, which suggests that PTP1B may modulate breast cancer progression through its effects on invadopodia. Collectively, our experiments implicate a novel signaling pathway involving calpain 2, PTP1B, and Src in the regulation of invadopodia and breast cancer invasion.

1 August 2011 in Trends in Cell Biology
Verified
Journal Article
Closed access
KCKeefe T. Chan
Keefe T. Chan
SCSarah J. Creed
Sarah J. Creed
JBJames E. Bear
James E. Bear

26 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
Elaine SanijElaine Sanij
Elaine Sanij
KHKatherine M. Hannan
Katherine M. Hannan
JXJiachen Xuan
Jiachen Xuan
SYShunfei Yan
Shunfei Yan
JAJessica E. Ahern
Jessica E. Ahern
RPRichard B. Pearson
Richard B. Pearson
Acquired resistance to PARP inhibitors (PARPi) is a major challenge for the clinical management of high grade serous ovarian cancer (HGSOC). Here, we demonstrate CX-5461, the first-in-class inhibitor of RNA polymerase I transcription of ribosomal RNA genes (rDNA), induces replication stress and activates the DNA damage response. CX-5461 co-operates with PARPi in exacerbating replication stress and enhances therapeutic efficacy against homologous recombination (HR) DNA repair-deficient HGSOC-patient-derived xenograft (PDX) in vivo. We demonstrate CX-5461 has a different sensitivity spectrum to PARPi involving MRE11-dependent degradation of replication forks. Importantly, CX-5461 exhibits in vivo single agent efficacy in a HGSOC-PDX with reduced sensitivity to PARPi by overcoming replication fork protection. Further, we identify CX-5461-sensitivity gene expression signatures in primary and relapsed HGSOC. We propose CX-5461 is a promising therapy in combination with PARPi in HR-deficient HGSOC and also as a single agent for the treatment of relapsed disease.

1 December 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CDCatherine Dietrich
Catherine Dietrich
ATAlec Trub
Alec Trub
AAAntonio Ahn
Antonio Ahn
MTMichael Taylor
Michael Taylor
KAKrutika Ambani
Krutika Ambani
SGShom Goel
Shom Goel
Cyclin-dependent kinase 2 (CDK2) is thought to play an important role in driving proliferation of certain cancers, including those harboring CCNE1 amplification and breast cancers that have acquired resistance to CDK4/6 inhibitors (CDK4/6i). The precise impact of pharmacologic inhibition of CDK2 is not known due to the lack of selective CDK2 inhibitors. Here we describe INX-315, a novel and potent CDK2 inhibitor with high selectivity over other CDK family members. Using cell-based assays, patient-derived xenografts (PDX), and transgenic mouse models, we show that INX-315 (i) promotes retinoblastoma protein hypophosphorylation and therapy-induced senescence (TIS) in CCNE1-amplified tumors, leading to durable control of tumor growth; (ii) overcomes breast cancer resistance to CDK4/6i, restoring cell cycle control while reinstating the chromatin architecture of CDK4/6i-induced TIS; and (iii) delays the onset of CDK4/6i resistance in breast cancer by driving deeper suppression of E2F targets. Our results support the clinical development of selective CDK2 inhibitors. Significance: INX-315 is a novel, selective inhibitor of CDK2. Our preclinical studies demonstrate activity for INX-315 in both CCNE1-amplified cancers and CDK4/6i–resistant breast cancer. In each case, CDK2 inhibition induces cell cycle arrest and a phenotype resembling cellular senescence. Our data support the development of selective CDK2 inhibitors in clinical trials. See related commentary by Watts and Spencer, p. 386. This article is featured in Selected Articles from This Issue, p. 384

1 June 2012 in Cancer Cell
Verified
Journal Article
Closed access
WLWenjin Liu
Wenjin Liu
KMKimberly B. Monahan
Kimberly B. Monahan
APAdam D. Pfefferle
Adam D. Pfefferle
TSTakeshi Shimamura
Takeshi Shimamura
JSJessica Sorrentino
Jessica Sorrentino
NSNorman E. Sharpless
Norman E. Sharpless